Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy
Open Access
- 1 February 2019
- journal article
- review article
- Published by Elsevier in Sleep Medicine Reviews
- Vol. 43, 23-36
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- Amygdala Lesions Reduce Cataplexy in Orexin Knock-Out MiceJournal of Neuroscience, 2013
- Role of the Medial Prefrontal Cortex in CataplexyJournal of Neuroscience, 2013
- Neurons as targets for T cells in the nervous systemTrends in Neurosciences, 2013
- Early IVIg treatment has no effect on post-H1N1 narcolepsy phenotype or hypocretin deficiencyNeurology, 2012
- Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in chinaAnnals of Neurology, 2011
- Medical exposures in youth and the frequency of narcolepsy with cataplexy: a population‐based case–control study in genetically predisposed peopleJournal of Sleep Research, 2010
- Hypocretin-2 Saporin Lesions of the Ventrolateral Periaquaductal Gray (vlPAG) Increase REM Sleep in Hypocretin Knockout MicePLOS ONE, 2009
- Effects of Modafinil on Dopamine and Dopamine Transporters in the Male Human BrainJAMA, 2009
- Localization of the Brainstem GABAergic Neurons Controlling Paradoxical (REM) SleepPLOS ONE, 2009
- The distribution of γ-hydroxybutyrate-induced Fos expression in rat brain: Comparison with baclofenNeuroscience, 2009